Calming fears that ACA would overburden the healthcare industry

With 10 million individuals in the U.S. now on insurance rolls thanks to the Affordable Care Act, many worried that the already overburdened industry would burst at the seams. A UCLA study appears to put some of those concerns to rest, reports California Healthline.

While there was an initial increase in utilization for California consumers, after the first few months, “there’s a dramatic drop-off,” according to researcher Gerald Kominski in the UCLA’s Center for Health Policy Research.

Read more below:

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.